Home > Focus Areas > DLBCL Connect > Post
  • Saved

4yr

The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy

The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy

Source : https://doi.org/10.1080/10428194.2020.1869965

Abstract We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a median follow-up of 31.1 months (95% CI 27.4 − 34.8), 4 relapses occurred.

  • 4yr
    There is a paucity of data on the prognostic and predictive value of subtyping limited stage DLBCL. Unfortunately this was not a homogeneously treated cohort which makes definitive conclusions on how to differentially handle subtypes with limited stage DLBCL impossible.

You might also like